Recently many investigators have found that platelet glycoprotein GP IIb/IIIa is responsible for platelet aggregation and plays a pivotal role in acute coronary thrombosis. Thus, GP IIb/IIIa antagonists may play an important role by inhibiting platelet aggregation and their binding to fibrinogen. Drugs that antagonize this binding have been developed for the treatment of thrombotic diseases and acute coronary syndrome. Now, there are three group of platelet receptor antagonists: monoclonal antibodies, synthetic peptides and non-peptide antagonists. As a result of large clinical trials the potency of those compounds in preventing of coronary thrombosis have been demonstrated. In this article molecular aspects of GP antagonists action and selected clinical trials have been presented.